Corporate · Global B2B
Evidence & Validation

Publications and technical resources, organized for review.

X-ZELL evidence across a foundational 2018 methods paper, the MVZ Frankfurt time-motion study, IOL Ljubljana FNA preliminary results, and 2026 Cryophore validation.

Selected evidence

Evidence timeline.

2018

Seven-fluorophore widefield IF method

Bhakdi SC, Thaicharoen P. Methods Protoc. 2018;1(2):20

Foundational method paper for crosstalk-free detection of seven fluorophores in widefield fluorescence microscopy.

Open DOI
2023

MVZ Frankfurt time-motion study

Grote, Bhakdi, Thaicharoen, Battmann. X-ZELL Research Report 2023

Deck source for turnaround, handling, data-yield, and workflow-consolidation figures.

View performance
2026

IOL Ljubljana FNA preliminary results

Miceska et al., Institute of Oncology Ljubljana

Peer-reviewed preliminary report on multiplex Cryoimmunostaining™ in FNA cytology.

Open DOI
2026

Cryophore™ multi-site IVDR validation

PDPROJ-55-VR-001 / PDPROJ-55-VR-007

Prospective validation at Halle and Frankfurt, with 100% concordance reported across all twelve antibodies after OOE resolution.

Validation summary
Reference sites

Implementation context and resources available on request.

Reference adoption across Germany, Singapore, and Slovenia.

Frankfurt, DE

Krankenhaus Nordwest - routine implementation listed from 2023.

Bochum, DE

Augusta Hospital - routine implementation listed from 2023.

Singapore, SG

Singapore General Hospital and National Cancer Centre Singapore - listed reference sites.

Halle, DE

Krankenhaus St. Elisabeth & St. Barbara - routine implementation listed from 2024.

Ljubljana, SL

Institute of Oncology Ljubljana - routine implementation listed from 2024.

Bangkok, TH

X-ZELL operations, lab, and clinic bridge the commercial and clinical footprint.

Evidence

Need source-level evidence for review?

The evidence dossier page summarizes the documents and topics that qualified institutions can request.

Evidence note: Clinical performance must be established in the intended patient-specimen context. Product availability, regulatory status, and intended use may vary by market. Please contact X-ZELL for current documentation.